The results showed that the cell viability inhibited by Ezetimibe was partially restored in HCC cells overexpressing NPC1L1 compared to those without NPC1L1 overexpression (Figure 6D and Figure S6A), demonstrating that Ezetimibe decreases cell survival by targeting NPC1L1. This evidence concerns the gene NPC1L1 and hepatocellular carcinoma.